総説
SGLT2 阻害薬はなぜ非糖尿病患者においても心・腎保護的か？
2021 年 52 巻 6 号 p. 157-164
詳細
2021 年 52 巻 6 号 p. 157-164
Evidence has emerged as to the cardio-renal protective effect of sodium glucose co-transporter 2 (SGLT2) inhibitors. Recent studies, DAPA‒CKD, DAPA‒HF and EMPEROR-Reduced and EMPEROR-Preserved will extend its clinical indications to heart failure and CKD even in patients without diabetes mellitus. This review anew discusses the presumable pharmacological mode of action with SGLT2 inhibitors in non-diabetics. The putative mechanisms by which SGLT2 inhibitors exert the beneficial effects may be accounted for by salt/water diuresis via SGLT2 and Na/H exchanger 3 inhibition, glucosuria-induced osmotic diuresis, and the subsequent optimization of tubule-glomerular feedback system in the kidney.
